Hadassah

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Monday, Aug 14 2017

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

CDI, often also called C. difficile, is caused by a bacterial toxin that inflames the colon. It is especially found in hospitals and long-term, in-patient care facilities. Approximately 500,000 people annually contract CDI in the U.S. alone and about 20 percent experience a recurrence.

The new product, called IMM-529, is a naturally produced biological antibody, intended to prevent and treat CDI, as well as stop recurrence. As a polyclonal antibody, it generates highly specific antibodies to fight the three main sources of CDI: Toxin B, the highly infectious spores, and the vegetative cells in the gut. In addition, IMM-529 has been shown to rebalance the diversity of bacteria in the gut, which is often disrupted by antibiotics.

This first-ever human study will assess whether IMM-529 is safe and well tolerated by the participants and will also evaluate the preliminary efficacy of IMM-529. Pre-clinical studies with mice at Monash University in Melbourne, Australia, revealed 80 percent efficacy in preventing and treating CDI and 77.8 percent success in preventing recurrence. The control group of mice, in contrast, which only received the standard-of-care antibiotic, vancomycin, experienced a mortality rate of 88.9 percent.

In this human trial, 60 patients who have been diagnosed with CDI and treated with standard-of-care antibiotics, will be enrolled within three weeks of their diagnosis. Some will be randomly selected to receive IMM-529 three times daily and the others will receive a placebo for 28 days.

Read more at: http://www.immuron.com/assets/Uploads/Red-Chip-C-Difficile-Analyst-Report-Jan-2016.pdf

Read about another IMMURON clinical trial at Hadassah http://www.hadassah.org/news-stories/fatty-liver-us-trials.html

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Sep 14 2017

Hadassah's Head of Emergency Medicine Springs to Action at Bar Mitzvah

Dr. Jacob (Koby) Assaf, head of Emergency Medicine at Hadassah Hospital Ein Kerem, was at a family Bar Mitzvah in a Jerusalem hotel when suddenly a 60-year-old man collapsed right next to him.

READ MORE ›
alt_text

Thursday, Sep 14 2017

Professor, Grandfather, and Cancer Survivor: A Hadassah Story

Following a consultation with Hadassah Endocrinologist and NET specialist Dr. Simona Glasberg, Prof. Bruins underwent numerous tests to determine the source and extent of penetration of this slow-developing type of cancer.

READ MORE ›
alt_text

Thursday, Sep 7 2017

Upgraded Sperm Bank Inaugurated at Hadassah-Mt. Scopus

A spacious, upgraded sperm bank and new laboratories have been inaugurated at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Thursday, Sep 7 2017

Study by Renowned Hadassah Neuropsychiatrist Featured in The Lancet

The work of Dr. Shahar Arzy, head of the Hadassah Medical Organization’s Neuropsychiatry Clinic and the Hadassah-Hebrew University Computational Neuropsychiatry Laboratory, is featured in the September 4, 2017 issue of The Lancet Psychiatry.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More